APOE and Alzheimer disease: The complex interplay between the genetic architecture, sex, and age of patients indicates the incorporation of these risk factors in both treatment planning and enrollment in clinical trials for identifying cognitively normal APOE ε4 carriers progressing to AD (Riedel et al., 2016).